Homing of radiolabelled xenogeneic equine peripheral blood-derived MSCs towards a joint lesion in a dog

Abstract

Osteoarthritis (OA) is a highly prevalent condition in dogs, causing a substantial reduction in quality of life and welfare of the animals. Current disease management focusses on pain relief but does not stop the progression of the disease. Therefore, mesenchymal stem cells (MSCs) could offer a promising disease modifying alternative. However, little is known about the behavior and the mode of action of MSCs following their administration. In the current case report, 99mTechnetium labelled xenogeneic equine peripheral blood-derived MSCs were intravenously injected in a 9 year old dog suffering from a natural occurring cranial cruciate ligament rupture. The biodistribution of the MSCs was evaluated during a 6-h follow-up period, using a full body scintigraphy imaging technique. No clinical abnormalities or ectopic tissue formations were detected throughout the study. A radiopharmaceutical uptake was present in the liver, heart, lung, spleen, kidneys and bladder of the dog. Furthermore, homing of the radiolabelled MSCs to the injured joint was observed, with 40.61 % higher uptake in the affected joint in comparison with the healthy contralateral joint. Finally, a local radioactive hotspot was seen at a part of the tail of the dog that had been injured recently. The current study is the first to confirm the homing of xenogeneic MSCs to a naturally occurring joint lesion after IV administration.

Comparative Effects of Intra-Articular versus Intravenous Mesenchymal Stromal Cells Therapy in a Rat Model of Osteoarthritis by Destabilization of Medial Meniscus

“…However, in that study, MSCs-IVt was performed immediately after the procedure, which is known to elicit inflammatory response within the first day [34]. Similarly, in a case study involving a dog with ACL rupture and synovitis, in vivo homing was observed 6 h after MSC-IVt [35]. Histological evidence also supports labeled MSCs within knee joint structures following IVt [13,16].…”

The Role of Mesenchymal Stem Cells in Modulating the Breast Cancer Microenvironment

“…MSCs are multipotent stem cells that have the potential to differentiate into several types of progenitor cells (such as adipocytes, osteoblasts, and myoblasts), and are involved in the maintenance and regeneration of connective tissues 20 . They can be separated from numerous tissue types, such as bone marrow (BM) 21 , adipose tissue (AT) 22 , dental pulp 23 , peripheral blood 24 , hair follicle 25 , lungs 26 , the placenta 27 , the umbilical cord (UC) 28 , UC blood, Wharton’s jelly 29 , amnion 30 , and chorion 31 . Among these, MSCs derived from BM, AT, and UC are the three most utilized in preclinical and clinical research 32 .…”